Effect of Teneligliptin on QT Interval in Type II Diabetes Mellitus Patients: A Retrospective Evaluation
Journal Title: INTERNATIONAL JOURNAL OF SCIENTIFIC STUDY - Year 2019, Vol 6, Issue 10
Abstract
Background and Aim: According to a strict QT/QTc evaluation study and clinical studies for type 2 diabetes conducted in Japan and other countries, NO AEs related to QT prolongation were detected with 40 mg/day of teneligliptin, which is the maximal dosage used in clinical practice. So far, there are no data regarding the safety of teneligliptin in Indian type 2 diabetic patients with respect to QTc prolongation. Therefore, the study was conducted to evaluate the safety of teneligliptin in type 2 diabetic patients with respect to QT prolongation. Methods: A retrospective data were collected from type 2 diabetes mellitus patients with electrocardiogram (ECG) records who were treated with teneligliptin along with ongoing treatment. Primary endpoint was to compare the change in the ECG at 3 months from the baseline from the collected data. Mean daily dose (MDD) of antidiabetic drugs, HbA1c, fasting plasma glucose (FPG), and postprandial plasma glucose (PPG) was also analyzed. Results: A total of 49 patients’ data were collected and analyzed with a mean age of 55.5 years and mean duration of diabetes 9.3 years. Hypertension was the most common comorbid disease (63.3%) along with diabetes for a mean duration of 10.0 years. Metformin plus glimepiride were the most prescribed dual drugs (63.3%) along with teneligliptin with an overall MDD of metformin (1065.2 mg) and glimepiride (2.1 mg). From the collected data, there was significant reduction in FPG and PPG at 3 months which were 49.6 mg/dL (P < 0.0001) and 100.5 mg/dL (P < 0.0001) reduction observed from the baseline, respectively. Significant changes were observed in the HbA1c from the baseline to 3 months (0.9%, P < 0.0001). There was no significant increase in the mean QTc interval from baseline to 3 months. No serious adverse events or hypoglycemia were reported. Conclusion: Teneligliptin was well tolerated with no significant change in QTc prolongation and significantly effective in reducing the FPG, PPG, and HbA1c at 3 months from the baseline with no adverse events. There was no increase in the mean QT interval.
Authors and Affiliations
S Sengupta, Ameet Rathod, H Barkate, A Pethare
Keywords
Related Articles
- EP ID EP483762
- DOI -
- Views 122
- Downloads 0
Surgery for Carcinoma of Esophagus Pyloroplasty - Is it a Boon or Bane to the Patient?
Background: Pyloroplasty is a pyloric drainage procedure routinely done during transhiatal esophagectomy (THE) or video-assisted thoracoscopic surgery (VATS) to prevent delayed gastric emptying resulting from truncal vag...
A Clinical Analysis of Facial Nerve Paralysis due to Inflammatory Diseases of the Middle Ear and the Role of Early Decompression
Background: Facial nerve (FN) paralysis is one of the most common intratemporal complications of inflammatory diseases of the middle ear. The pathology of FN paralysis in inflammatory diseases of the middle ear is an ero...
A Retrospective Survey to Assess the Skin Lightening, Skin Moisturization and Sensorial Properties of a Broad Spectrum Sunscreen Formulation in Indian Patients
Introduction: Indian people primarily use sunscreens to prevent tanning and maintain a fair complexion rather than preventing sunburns and cancers which are the internationally recommended reasons for use of sunscreens....
Prevalence of Silent Ischemic Heart Disease in Patients of Rheumatoid Arthritis
Background: Almost half of the deaths in patients of rheumatoid arthritis (RA) are due to cardiovascular diseases. Many studies have shown that patients of RA are at increased risk of mortality and morbidity from ischemi...
Screening for Acanthosis Nigricans in Type 2 Diabetes Mellitus - It’s Time for Reinforcement
Background: Acanthosis nigricans is a well-known external marker for insulin resistance, obesity and type 2 diabetes mellitus (T2DM). The prevalence of acanthosis varies among different ethnic groups. Aim: The aim of the...